Novo Nordisk (NVO) has cut the listing prices by half for its obesity drug Wegovy in some Chinese provinces as the company prepares for copycats to flood the market, Amber Tong of Bloomberg reports, citing local media Yicai. The listing prices for the company’s two highest doses of Wegovy were cut to 987.48 yuan and 1,284.36, respectively, Yicai reported, citing drug-procurement documents for Yunnan and Sichuan provinces.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Soars as Wegovy Pill Changes the Game
- GLP-1 Pills Gain Ground: Novo Nordisk Wins FDA Nod as Food Giants Tweak Strategy
- Mixed options sentiment in Novo Nordisk with shares up 1.79%
- Lilly vs. Novo Nordisk: Who Will Lead India’s Growing Obesity-Drug Market?
- Novo Nordisk Expands Cardiovascular Ambitions With New Phase 3 Ziltivekimab Plaque Study